Aberdeen Group plc Lowers Stock Holdings in LivaNova PLC $LIVN

Key Points

• Aberdeen Group cut its LivaNova stake by 89.5% in Q4, selling 220,443 shares and leaving it with 25,850 shares valued at $1.591 million.
• Several large institutions—incl. Artisan, Wellington, Invesco and Millennium—significantly increased positions, and institutional investors collectively own 97.64% of the stock.
• LivaNova beat Q results (EPS $0.86 vs. $0.80; revenue $360.92M, +12.2% YoY), set FY2026 guidance of 4.150–4.250 EPS, and has a MarketBeat consensus rating of "Moderate Buy" with an average price target of $74.78.

Aberdeen Group plc trimmed its position in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 89.5% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 25,850 shares of the company's stock after selling 220,443 shares during the quarter. Aberdeen Group plc's holdings in LivaNova were worth $1,591,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in LIVN. Artisan Partners Limited Partnership boosted its stake in shares of LivaNova by 94.5% in the 3rd quarter. Artisan Partners Limited Partnership now owns 2,427,045 shares of the company's stock valued at $127,129,000 after buying an additional 1,179,436 shares during the period. Wellington Management Group LLP boosted its stake in shares of LivaNova by 83.5% in the 3rd quarter. Wellington Management Group LLP now owns 2,345,516 shares of the company's stock valued at $122,858,000 after buying an additional 1,067,349 shares during the period. Invesco Ltd. boosted its stake in shares of LivaNova by 714.7% in the 2nd quarter. Invesco Ltd. now owns 1,028,713 shares of the company's stock valued at $46,313,000 after buying an additional 902,447 shares during the period. Scopia Capital Management LP acquired a new stake in shares of LivaNova during the 2nd quarter worth about $36,657,000. Finally, Millennium Management LLC raised its position in shares of LivaNova by 22.4% during the 3rd quarter. Millennium Management LLC now owns 2,969,814 shares of the company's stock worth $155,559,000 after acquiring an additional 544,033 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company's stock.

LivaNova Stock Down 2.0%

LivaNova stock opened at $63.37 on Friday. The company has a debt-to-equity ratio of 0.29, a current ratio of 1.36 and a quick ratio of 1.16. LivaNova PLC has a 1-year low of $32.65 and a 1-year high of $71.92. The company has a market cap of $3.47 billion, a PE ratio of -14.21 and a beta of 0.97. The stock's 50 day moving average price is $64.91 and its 200 day moving average price is $60.60.

LivaNova (NASDAQ:LIVN - Get Free Report) last posted its quarterly earnings results on Wednesday, February 25th. The company reported $0.86 earnings per share for the quarter, beating analysts' consensus estimates of $0.80 by $0.06. LivaNova had a positive return on equity of 16.54% and a negative net margin of 17.46%.The firm had revenue of $360.92 million for the quarter, compared to the consensus estimate of $354.31 million. During the same period in the previous year, the business earned $0.81 earnings per share. The company's revenue for the quarter was up 12.2% compared to the same quarter last year. LivaNova has set its FY 2026 guidance at 4.150-4.250 EPS. On average, sell-side analysts predict that LivaNova PLC will post 2.85 EPS for the current fiscal year.

Wall Street Analyst Weigh In

LIVN has been the topic of several research analyst reports. Robert W. Baird set a $75.00 target price on LivaNova in a research report on Tuesday, December 16th. Needham & Company LLC raised their target price on LivaNova from $64.00 to $81.00 and gave the stock a "buy" rating in a research report on Wednesday, February 25th. Stifel Nicolaus set a $80.00 target price on LivaNova in a research report on Wednesday, February 25th. Piper Sandler reaffirmed an "overweight" rating and set a $85.00 price target on shares of LivaNova in a research report on Thursday, February 19th. Finally, Weiss Ratings reaffirmed a "sell (d+)" rating on shares of LivaNova in a research report on Friday, March 27th. Seven investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $74.78.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company's primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.

Want to see what other hedge funds are holding LIVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LivaNova PLC (NASDAQ:LIVN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.